Tadalafil Tablet
Product Images NDC 68071-3598

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc.., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3598 6)

This text contains information from a pharmaceutical product label. It includes details such as the manufacturer, lot number, NDC numbers, expiration date, dosage, and storage instructions. It also provides a warning to keep the product out of reach of children and store at a controlled temperature of 68-77°F.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This appears to be a table with headings for blood pressure measurements in standing and supine positions, measuring both diastolic and systolic readings over time in hours. The exact values are not provided in the text.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This text provides a table showing the "Standing Systolic BP (mmHg)" and mentions the combination of Tadalafil 20 mg & doxazosin 8 mg. It seems to be related to a medical context, possibly a study or a report on blood pressure and medication.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

This text seems to be showing a comparison of systolic blood pressure readings at different time points after the administration of different medications like tadalafil and doxazosin. It also mentions the dosage and timing of these medications. This information can be used to understand the effects of these medications on blood pressure.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

This text is discussing the IPSS Total Score and the change from the baseline for Tadalafil tablets 5 mg compared to a placebo over a duration of treatment in weeks. It also indicates a statistically significant difference between the groups with a p-value of less than 0.001.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

This text describes the LS mean change from baseline for Tadalafil Finasteride compared to Placebo Finasteride, showing the least squares treatment difference.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This text provides information about a study involving Tadalafil tablets at a 5mg dosage compared to a placebo, with statistical significance denoted by the asterisk and a p-value of less than 0.01. The graph depicts the duration of treatment in weeks, showing a comparison over time.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.